Thyroid function in older adults is a highly complex clinical field because aging modifies the set-points of the hypothalamic-pituitary-thyroid axis, hormone pharmacokinetics, and the vulnerability of target organs to excessive or deficient thyroid hormone signaling. In this age group, clinical manifestations are often attenuated or masked by cardiovascular comorbidities, frailty, sarcopenia, and polypharmacy, while the consequences of a therapeutic error may be more significant than in younger adults, particularly in terms of atrial fibrillation, heart failure, fractures, and functional decline.
From an epidemiological perspective, the prevalence of thyroid nodularity and thyroid-stimulating hormone (TSH) abnormalities increases with age, while the pre-test probabilities of the main diagnoses change: subclinical hypothyroidism becomes more common and does not always require treatment, hyperthyroidism may present as apathetic hyperthyroidism with few adrenergic signs, and nodular thyroid disease, although associated on average with a lower risk of malignancy per individual nodule, may involve more aggressive histological subtypes when carcinoma is present. Modern management therefore requires a medicine of balance, based on realistic goals, cautious dose titration, and shared decision-making, with constant attention to the risk-benefit ratio for the individual patient.
Aging is associated with gradual changes in the hypothalamic-pituitary-thyroid axis and in the peripheral dynamics of thyroid hormones. In practical terms, this means that the same TSH value may have a different clinical significance than in a younger adult, particularly when the abnormality is mild and stable over time. A proportion of older adults have moderately elevated TSH with free thyroxine (FT4) within the reference range, without clear clinical signs or rapid progression. In this setting, the likelihood of benefit from treatment is not automatic and must be weighed against the risk of overtreatment.
Interpretation of laboratory tests must also take into account the higher prevalence of non-thyroidal conditions that transiently alter TSH and free hormone concentrations, including acute illness, malnutrition, renal failure, liver disease, and systemic inflammation. In frail or hospitalized patients, the hormonal profile may reflect an adaptive response to stress or illness rather than primary thyroid dysfunction, and unnecessary pharmacological intervention may further destabilize the clinical condition. In this context, the most informative finding is often not a single measurement, but its persistence and reproducibility after several weeks, when the patient is clinically more stable.
A specific aspect in older adults is the effect of transport proteins and changes in hormone binding, which may make the interpretation of total hormone concentrations misleading and, in some situations, may also affect the reliability of free hormone assays. Methodological consistency during follow-up is therefore a simple but essential principle: whenever possible, using the same laboratory and the same assay method reduces apparent fluctuations and supports safer decisions, particularly when small dose adjustments are being considered.
Polypharmacy is an additional determinant of interpretation. Medications that interfere with levothyroxine absorption, peripheral metabolism, or protein binding are more common in older adults and may explain unstable TSH concentrations or an apparent need for repeated dose increases. Clinical reasoning must therefore precede dose escalation: before increasing or reducing the dose, adherence, timing of administration, interactions, and recent changes in concomitant treatment should be assessed.
Finally, the safety margin is narrower in older adults. Excessive thyroid hormone signaling, even when subclinical, tends to manifest through cardiovascular and skeletal complications. Conversely, a prolonged deficiency may worsen dyslipidemia, reduce exercise tolerance, and contribute to frailty and psychomotor slowing. Test interpretation must therefore be intrinsically clinical: laboratory values are tools, but the decision arises from their integration with symptoms, functional goals, and individual risk.
Hypothyroidism in older adults may present with nonspecific symptoms that often overlap with aging or comorbidities, including fatigue, modest weight gain, cold intolerance, constipation, dry skin, reduced physical performance, and cognitive slowing. Because these manifestations are also common in the absence of thyroid dysfunction, diagnosis must be based on an appropriate biochemical assessment and evaluation of the pre-test probability, including a history of autoimmune thyroiditis, previous surgery, radioiodine treatment, or exposures that reduce thyroid reserve.
The most frequent decision-making issue is subclinical hypothyroidism, defined by elevated TSH with FT4 within the reference range. In older adults, a substantial proportion of cases remain stable and do not progress, and the safest approach is to confirm persistence of the abnormality and assess autoimmunity and the clinical context before starting treatment. When TSH is markedly elevated or when consistent and persistent symptoms are present, the potential benefit of replacement therapy becomes more plausible, but it must still be balanced against the risk of overtreatment, which is particularly harmful in older adults.
In overt hypothyroidism, with reduced FT4, treatment with levothyroxine is indicated, but initiation differs from that in younger adults. The clinical principle is cautious titration, particularly in the presence of ischemic heart disease, heart failure, arrhythmias, or frailty. An excessively rapid increase in thyroid hormone signaling may raise myocardial oxygen consumption and precipitate angina or electrical instability. Conversely, excessively slow correction in severe and symptomatic forms may prolong a deficiency that worsens functional independence. The rate of titration must therefore be individualized and depends on severity, cardiovascular history, and the patient’s goals.
Targets must be realistic. In older adults, the aim is not to pursue a theoretically perfect value, but to achieve a balance that improves symptoms and the metabolic profile while avoiding suppressed or borderline-low TSH concentrations. This concept is central because one of the most frequent complications of treatment is iatrogenic hyperthyroidism, which often remains unrecognized when TSH is not monitored regularly or when a dose prescribed many years earlier is left unchanged. Periodic follow-up, even when the patient is stable, is therefore a safety measure rather than a formality.
Another practical consideration is the management of interference with absorption. Iron, calcium, antacids, binding resins, supplements, and medications that alter gastric motility or acidity are common in older adults and may all reduce levothyroxine absorption. Before attributing an elevated TSH concentration to disease progression, impaired absorption or inappropriate timing of administration should be considered. This reduces unnecessary dose escalation and prevents fluctuations that alternately expose the patient to hypothyroidism and hyperthyroidism.
Hyperthyroidism in older adults is clinically dangerous even when the typical adrenergic signs are attenuated. It may present with weight loss, fatigue, worsening heart failure, angina, dyspnea, mild or absent tremor, and mood disturbances, producing clinical pictures that may be mistaken for progression of heart disease or frailty. In some patients, apathy, depression, and reduced social interaction predominate, which is why thyrotoxicosis may be diagnosed late unless thyroid dysfunction is considered in the differential diagnosis of subacute functional deterioration.
The main risk is cardiovascular. Excess thyroid hormones increase heart rate, contractility, oxygen consumption, and electrical instability, promoting atrial fibrillation and, consequently, thromboembolic events. Subclinical thyrotoxicosis, with suppressed TSH and free hormones within the reference range, may also be associated with an increased risk of atrial fibrillation and worsening cardiac performance, particularly in patients with pre-existing structural heart disease. In this age group, careful assessment of the degree of TSH suppression and its persistence over time is essential when deciding whether treatment is required and how urgently it should be initiated.
From an etiological perspective, hyperthyroidism caused by functional autonomy, such as toxic multinodular goiter or a toxic nodule, is more common in older adults, whereas Graves disease may be less prevalent than in younger individuals, although it remains possible. This distinction guides treatment strategy: antithyroid medications may be used for initial control, but the choice of definitive treatment and management of the comorbidity burden often require individualized planning. The choice among prolonged medical therapy, radioiodine, and surgery must take into account frailty, anesthetic risk, goiter size, compressive symptoms, adherence, and patient preferences.
Pharmacological management should include symptomatic control, often with beta-blockers when not contraindicated, and close monitoring, because older adults are more vulnerable to adverse effects and to the consequences of overtreatment. The aim is to return the patient promptly to a safe hormonal range while avoiding both persistent thyrotoxicosis and iatrogenic hypothyroidism. In particular, in patients with weight loss and sarcopenia, normalization of thyroid hormone signaling is part of the functional recovery strategy, but it must proceed with careful attention to cardiac parameters and nutritional status.
In older patients, thyroid function interacts directly with major determinants of frailty, including muscle mass, balance, bone mineral density, and risk of falls. Hyperthyroidism, including its subclinical form, increases bone turnover and accelerates bone loss, promoting osteoporosis and fractures, with a particularly relevant effect in postmenopausal women. Hypothyroidism may contribute to reduced physical performance, stiffness, and slowing, aggravating sarcopenia and fall risk through multifactorial mechanisms that include reduced aerobic capacity, neuromuscular abnormalities, and worsening mood.
This explains why therapeutic targets must be selected cautiously. Chronically suppressed TSH caused by levothyroxine overtreatment, a scenario that is not uncommon when treatment remains unchanged for years, may act as iatrogenic subclinical thyrotoxicosis and increase the risk of atrial fibrillation and fractures. In older adults, being slightly overtreated is not a minor error because cardiovascular and skeletal compensatory reserves are reduced. Prevention requires periodic monitoring, reassessment of dose requirements over time, and attention to changes in body weight and comorbidities.
In practical terms, when an older patient presents with fragility fractures, loss of height, vertebral pain, or sudden worsening of balance, thyroid assessment is a useful component of clinical reasoning, particularly when tachycardia, weight loss, or suppressed TSH coexist. Similarly, in a patient with progressive functional decline and sarcopenia, unrecognized hypothyroidism may represent a reversible factor that adds to other determinants. The aim is not to attribute an exclusive role to the thyroid, but to identify and correct a modifiable contribution that may improve independence and quality of life.
Finally, thyroid treatment must be integrated with bone health management. In the presence of osteoporosis or a high fracture risk, prevention of overtreatment is a priority and may require more conservative targets and closer TSH monitoring. This is particularly relevant in older women, patients with a history of fractures, and individuals taking medications that increase the risk of osteoporosis. In older adults, the thyroid therefore becomes an integral component of overall functional prognosis.
Thyroid nodularity increases with age and is a frequent incidental ultrasound finding. In older adults, the challenge is not only to identify a nodule, but also to determine whether its characterization and possible treatment will meaningfully alter prognosis and quality of life. The risk of malignancy per individual nodule may be lower on average than in younger patients, but when carcinoma is present, the likelihood of more aggressive biological features and poorer outcomes increases. Appropriate risk stratification based on ultrasound and, when indicated, fine-needle aspiration is therefore essential.
The diagnostic approach remains based on ultrasound assessment of suspicious features, nodule size, and lateral cervical lymph nodes. The decision to perform fine-needle aspiration must integrate ultrasound risk with the patient’s condition, including frailty, anticoagulant treatment, comorbidities, and goals of care. In some cases, particularly in nodules with a low-risk ultrasound pattern in patients with limited life expectancy or high procedural risk, surveillance may be the most appropriate choice. In other cases, high-risk ultrasound features, significant growth, or suspicious lymph nodes require a complete diagnostic pathway because timely diagnosis may change management and prognosis.
In older patients, oncological treatment decisions must be proportionate. Surgery may be curative but carries greater risks in the presence of frailty and comorbidities, whereas radioiodine and TSH-suppressive treatment with levothyroxine require careful assessment to avoid cardiovascular and skeletal complications. The safest strategy is multidisciplinary and based on a realistic estimate of the expected benefit, distinguishing low-risk tumors that can be managed conservatively from tumors with a stronger indication for active treatment. In all cases, the goal is not to treat the nodule, but to treat the patient through decisions that are consistent with individual risks and life goals.
Thyroid treatment in older adults is guided by the principle of safety: titration should be slow when cardiovascular risk is high, monitoring should be regular, and iatrogenic hyperthyroidism should be prevented. When levothyroxine replacement therapy is initiated, body weight, frailty, and comorbidities must be considered, with gradual dose increases and follow-up assessments that allow evaluation of the clinical and biochemical response. Even when hypothyroidism is clearly established, replacement does not necessarily need to be rapid in every patient because an older individual may not tolerate a sudden increase in myocardial oxygen consumption.
Polypharmacy requires structured counselling. Levothyroxine administration should be separated from iron, calcium, and binding resins, and its timing in relation to meals and other medications should remain consistent to reduce fluctuations. If TSH remains elevated despite dose increases, impaired absorption and poor adherence should be considered before the dose is increased further. This reduces the risk of dose stacking, with progressive increases that become excessive once the interference is removed or the patient’s routine changes.
In the treatment of hyperthyroidism, the selected strategy must minimize the risk of adverse events and take adherence into account. Medical therapy may be appropriate in certain settings, but it requires monitoring and attention to signs of toxicity. Radioiodine may provide a definitive solution in many forms of functional autonomy, but it must be planned by considering goiter size, cardiac function, and the need for symptomatic control before the procedure. Surgery is reserved for selected scenarios, particularly compressive goiters, suspected malignancy, or contraindications to other options, and requires careful anesthetic and geriatric assessment.
Long-term monitoring is a key component of management. Thyroid function and levothyroxine requirements may change with aging, weight loss, intercurrent illnesses, and modifications to concomitant treatment. Periodic TSH measurement, even in stable patients, is therefore a preventive measure against overtreatment. In older adults, avoiding chronically suppressed TSH is a priority to reduce the risk of atrial fibrillation and fractures, while avoiding persistently elevated TSH in overt forms reduces the risk of functional decline and metabolic deterioration.
In summary, treatment in older adults requires a precision-based approach: the lowest effective dose, clinical and functional goals, regular reassessment, and systematic attention to interactions. This approach reduces iatrogenic complications and keeps thyroid function within a balance compatible with frailty and the individual risk profile.